Analysis of Henlius' H Medicine Hansizhuang Phase III Clinical Trial for Gastric Cancer

Based on my search results, no specific news reports about the success of Henlius’ H Medicine Hansizhuang Phase III clinical trial for gastric cancer can be found currently. However, based on public information, I can provide you with a detailed analysis of Henlius and its PD-1 inhibitor Hansizhuang (Serplulimab):

is a Chinese biopharmaceutical company focused on the research and development of biosimilars and innovative antibody drugs. Hansizhuang (Serplulimab) is the company’s self-developed PD-1 inhibitor, which has been approved in China for multiple solid tumor indications.

• Microsatellite Instability-High (MSI-H) Solid Tumors
  - Approved in 2022
• Squamous Non-Small Cell Lung Cancer (sqNSCLC)
  - Approved in 2022
• Esophageal Squamous Cell Carcinoma (ESCC)
  - Approved in 2023
• Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
  - Approved in 2023

Henlius is actively expanding the indication scope of Hansizhuang, including:

• Gastric cancer/gastroesophageal junction cancer
• Colorectal cancer
• Liver cancer
• Head and neck squamous cell carcinoma

Regarding the $30 billion potential you mentioned, this may refer to the overall market prospect of PD-1/PD-L1 inhibitors in solid tumor treatment:

1. Global PD-1/PD-L1 Market Size
   : Expected to exceed $30-50 billion by 2030
2. Gastric Cancer Treatment Field
   : As the fifth most common cancer globally, there is a huge unmet need for gastric cancer treatment
3. Perioperative Immunotherapy
   : Moving immunotherapy to before and after surgery may significantly improve patient prognosis

• Clinical trial data readout for new indications of Hansizhuang
• New indication approval from the National Medical Products Administration (NMPA)
• Regulatory approval progress in international markets

• Uncertainty of clinical trials
• Intense market competition (multiple PD-1/PD-L1 inhibitors already on the market)
• Price pressure from medical insurance negotiations

Regarding the specific news of the success of Henlius’ H Medicine Hansizhuang Phase III clinical trial for gastric cancer, it is recommended to pay attention to:

1. Company official announcements
2. Clinical trial registration database (ClinicalTrials.gov)
3. Data release from authoritative medical conferences (such as ASCO, ESMO)

If you can provide more specific news sources or time information, I can conduct more precise searches and analysis for you. In addition, it is recommended to follow Henlius’ official investor relations page to obtain the latest R&D progress.

---

• Henlius official website: https://www.henlius.com
• ClinicalTrials.gov clinical trial database
• Official releases from various academic conferences (ASCO, ESMO)